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Introduction
Public health programmes that address the threats of antimi-
crobial resistance and of tuberculosis are major contributors 
towards gains in global health.1,2 Unlike tuberculosis, antimi-
crobial resistance is not specifically mentioned in the health 
targets of United Nations’ sustainable development goal 3.3 
Both health issues, however, are encompassed in the overarch-
ing goal of ensuring healthy lives and promoting well-being 
for all. The globally endorsed End Tuberculosis strategy4 and 
Global Action Plan on Antimicrobial Resistance5 also agree on 
universal health coverage and collaboration between diverse 
stakeholders to achieve their objectives.
Despite potential synergies between them, antimicrobial 
resistance and tuberculosis have until recently been positioned 
as separate global health issues, and efforts aimed at controlling 
both remain primarily vertical (disease-specific). Integration 
across programme components has therefore been limited, 
possibly leading to economic inefficiencies and suboptimal 
service delivery. This is exemplified most clearly by the initial 
decision to exclude Mycobacterium tuberculosis from the 
global priority list of antibiotic-resistant bacteria,6 even though 
estimates suggest that by the year 2050 drug resistant tubercu-
losis will be responsible for 2.6 million of the total 10 million 
annual deaths associated with antimicrobial resistance.1,7 The 
protests and concerns raised following this decision eventually 
led to the inclusion of M. tuberculosis within the priority list, 
highlighting the importance of integrating activities aimed 
at addressing both health issues.8 A non-systematic review 
of studies on integration of programmes on maternal and 
child health, human immunodeficiency virus (HIV), sexually 
transmitted infections and tuberculosis found that integration 
increased uptake of services.9
Several antimicrobial agents used to treat tuberculosis are 
also used for management of other infectious diseases. These 
include fluoroquinolone antibiotics, which are used not only 
for tuberculosis, but also for respiratory, urinary and enteric 
infections. A systematic review and meta-analysis found that 
use of fluoroquinolones in patients with respiratory infections 
delayed the diagnosis of tuberculosis by nearly 2 weeks,10 thus 
emphasizing the interdependence of antimicrobial resistance 
and tuberculosis control efforts. Given such overlap, exposure 
to antimicrobial drugs risks development of resistance in other 
microorganisms.11
In this paper we summarize some opportunities and 
challenges to integration of tuberculosis and antimicrobial 
resistance programmes. We first summarize the synergies be-
tween high-level strategies on tuberculosis and antimicrobial 
resistance control. These provide a potential platform for the 
integration of programmes and illustrate how integration at 
the health-service delivery level for diagnostic services could 
occur in practice in a low and middle-income setting. We then 
discuss barriers to integration and identify opportunities and 
incentives to overcome these.
Synergies between programmes
Both the End Tuberculosis strategy and Global Action Plan 
on Antimicrobial Resistance aim to improve health and con-
trol infectious diseases and, in particular, to limit the spread 
of drug resistance. Therefore, despite differences in their 
organizational structure and funding streams, integrating 
certain activities will result in better use of resources and 
increase the likelihood of achieving mutual goals. The End 
Tuberculosis strategy already recognizes the importance of 
collaboration with other initiatives and programmes;4 in 
most countries, for example, tuberculosis programmes have 
experience of collaboration with HIV programmes. Similarly, 
many antimicrobial resistance programmes are being built 
on a One Health approach,12 recognizing the importance of 
engaging multiple partners, including those outside of the 
human health sector.
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Partial integration between individ-
ual health programmes can be achieved 
through linkages and collaborations, 
but full integration requires integration 
across the components of governance, 
financing, service delivery and infor-
mation systems.13 Integration between 
tuberculosis control and antimicrobial 
resistance programmes at the global 
level could promote shared activities 
within countries to achieve mutual 
benefits for both programmes (Box 1).
Integration of laboratory 
services
Over the last decade those involved in 
tuberculosis control have developed 
important new diagnostic tools and 
established quality-assured laboratory 
systems. As a result, detection of tuber-
culosis and in particular drug-resistant 
tuberculosis has greatly increased.2 
Tuberculosis control planners have 
experience in developing laboratory 
systems towards better quality assurance 
systems (such as in handling of sputum 
smears), standardized record-keeping 
and logistics support (including inter-
net connectivity, reporting to national 
programmes, supply chain manage-
ment and coordination of laboratory 
functions). These experiences could 
be leveraged to strengthen diagnostic 
laboratories involved in antimicrobial 
resistance testing and surveillance. In-
deed, the major initial focus of antimi-
crobial resistance control strategies is on 
surveillance, with large investments now 
being made to strengthen the often weak 
surveillance of antimicrobial resistance 
in low- and middle-income countries.14
A tuberculosis laboratory network 
generally has a tiered structure,15 with 
microscopy at the basic level, mycobac-
terial culture at the intermediate level, 
and culture as well as drug sensitiv-
ity testing at the reference laboratory 
level. Peripheral laboratories can offer 
point-of-care tests that will help to 
decrease antibiotic misuse by establish-
ing when diseases have a viral cause. 
At the intermediate level, laboratories 
can share culture and antibiotic sus-
ceptibility testing capacities to provide 
public health facilities with appropriate 
antimicrobial resistance diagnostics. 
Reference laboratories can contribute to 
confirmation of bacterial resistance and 
to surveillance for emerging resistance 
mechanisms in pathogens. Laborato-
ries in the tuberculosis network have 
well-established quality management 
systems and biomedical and biosafety 
infrastructures and, by using the same 
facilities for antimicrobial resistance, 
can bypass the need to create expensive 
systems in new laboratories dedicated 
to antimicrobial resistance.
Such a structure lends itself well to 
close cooperation and integration with 
antimicrobial resistance programmes. 
Several diagnostic tools currently in use 
for diagnosis of antimicrobial resistance, 
as well as existing infrastructure and 
human resources, could be adapted to 
facilitate the integration of services, and 
delivered in accordance with the level 
and expertise available at the relevant 
tuberculosis laboratories (Fig. 1). In 
remote areas where laboratory access 
for diagnosis of infectious diseases is 
limited, services provided by the most 
basic tuberculosis microscopy centres 
could be expanded to include point-
of-care testing for common infections. 
Some examples of point-of-care tests 
that could be incorporated into exist-
ing tuberculosis diagnostic services 
include malaria diagnosis, microscopy 
or dipstick testing for urinary tract 
infections as well as pneumococcal and 
Legionella antigen tests. This approach 
would be strengthened when combined 
with referral of specimens for culture 
and sensitivity testing and initiation of 
appropriate treatment to control further 
spread of resistant organisms. Recently, 
rapid molecular tests for tuberculosis 
are being added, particularly at the 
intermediate and reference levels, but 
in some cases also at the basic labora-
tory level. This system is underpinned 
by logistics support and greater efforts 
to expand connectivity for reporting 
and monitoring within the network. At 
the international level, the tuberculosis 
laboratory network is supported by sev-
eral supranational reference laboratories 
that provide training and on-the-ground 
assistance and advice as required.
Increasing the breadth of services 
provided by tuberculosis laboratories 
could be used to strengthen antimi-
crobial resistance diagnostic testing 
and surveillance. Currently, one of 
the most widely used rapid molecular 
test for detection of M. tuberculosis is 
Xpert® MTB-RIF (Cepheid, Sunnyvale, 
United States of America). The Xpert® 
technology, however, could also be used 
for the rapid diagnosis of several other 
bacterial and viral infections. The rep-
ertoire of infectious disease diagnostics 
is constantly expanding, based on new 
technologies including microfluidics16 
and film arrays.17,18 These could easily 
be placed in integrated intermediate 
level laboratories, with a wider test 
menu towards guided antimicrobial 
therapy. Finally, many of the suprana-
tional tuberculosis reference laborato-
ries have already confirmed that they 
could expand susceptibility testing for 
other pathogens if funding were avail-
able.19 Their expanded role could be 
leveraged as an opportunity towards 
self-sustainability by adding to the core 
competency of each laboratory and 
also an expanded role for tuberculosis 
laboratory networks.
Box 1. Benefits of integration between programmes for tuberculosis control and 
antimicrobial resistance
• Efficient use of resources currently allocated to separate tuberculosis control and 
antimicrobial resistance programmes towards coordinated prevention and control strategies.
• Sharing of expertise, local experience and existing resources, such as staff and health 
facilities, to enhance outcomes for both tuberculosis control and antimicrobial resistance 
programmes.
• Development of synergistic technical packages covering clinical guidelines, diagnostic 
pathways and tools, infection control and prevention, and evidence-based priority 
interventions. These could work towards controlling resistance in the Mycobacterium 
tuberculosis complex as well as bacteria in the global list of antibiotic-resistant priority 
pathogens.6
• Greater advocacy and political attention for both tuberculosis and antimicrobial resistance. 
Collaboration could intensify efforts towards improving the quality of care delivered by 
informal health-care providers, regulating the pharmaceutical industry and controlling the 
use of growth promoters in the veterinary industry.
• Reduced reliance on external resources, through integrating tuberculosis control and 
antimicrobial resistance programmes within the national structures of high-burden 
countries. In this way common goals would be safeguarded through a strengthened 
oversight mechanism.
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Another advantage is that the 
broader infrastructure could be shared 
between tuberculosis and antimicrobial 
resistance programmes. Low-resource 
settings face infrastructure challenges 
to providing laboratory services. These 
include shortages of trained laboratory 
staff; lack of access to biomedical techni-
cal support;20 problems with installing, 
validating, certifying and servicing 
laboratory equipment; difficulties in 
specimen transport;21 difficulties in 
data connectivity and management; 
and challenges to maintaining biosafety 
levels.22,23 While laboratory networks can 
be resource-intensive and expensive to 
run, they do lend themselves to serving 
more than one health programme, al-
lowing for optimal use of resources. For 
example, establishment of an efficient 
and far-reaching specimen referral net-
work has been explored by investigators 
in Ethiopia and Uganda, and shown 
to be effective for multiple diseases, 
including tuberculosis, HIV and hepa-
titis.21,24 Therefore, establishing shared 
laboratory spaces, equipment and sup-
plies, human resources and transport 
systems would be mutually beneficial 
to both tuberculosis and antimicrobial 
resistance programmes and improve 
universal access to diagnostics for the 
population served.
Benefits of integrated 
services
Integration of certain services in joint 
laboratories could have benefits for 
both tuberculosis and antimicrobial 
resistance programmes. In low-resource 
settings, expanding the scope of tests 
within the existing tuberculosis labora-
tory network would increase patients’ 
access to diagnostics and encourage 
rational use of antimicrobials. A recent 
study on the impact of rapid diagnostic 
tests for malaria in Africa and Asia 
demonstrated that while rapid diag-
nosis reduced antimalarial drug use, 
it also resulted in over-prescription of 
antimicrobial agents.25 This highlights 
the importance of not only enhancing 
access to diagnostics, but also coordinat-
ing between disease-specific laboratory 
networks and antimicrobial resistance 
control programmes.
Integration will also enhance the 
capacity of the tuberculosis laboratory 
network, enabling the facilities and staff 
to function beyond a single disease area, 
and thereby serve a larger population of 
patients. Broadening the patient popula-
tion served by joint laboratories for tu-
berculosis and antimicrobial resistance 
may also help to address the challenge of 
low research and development funding 
for tuberculosis diagnostics.26 As tuber-
culosis progresses towards elimination, 
for-profit companies see limited scope 
for financial returns on developing new 
diagnostics for the disease. Investing in 
diagnostics may be more attractive if 
companies are able to cater to a larger 
population with emerging diseases of 
various etiologies, For example, industry 
reports estimate that the market value 
of diagnostics for infectious diseases 
was worth 14.45 billion United States 
dollars (US$) in 2016 and expected to 
reach US$ 21.13 billion by 2021, with 
the global worth of point-of-care diag-
nostics expected to reach US$ 1.9 billion 
by 2025.27,28 With sufficient investment 
in research and development, there 
are opportunities for advancements in 
laboratory medicine. 
Many of the new tests being devel-
oped (including those for tuberculosis) 
are of low complexity and performed 
near the patient or at the point of 
care,29 which is more convenient and 
less costly for patients. The focus on 
patient-centred approaches has also led 
to the development of multiplex devices 
designed to rapidly detect a variety of 
bacterial, viral or fungal pathogens in 
a single test.30 Currently many of these 
technologies are of moderate complex-
ity, requiring technical expertise that 
Fig. 1. Diagnostic tools currently in use at different levels of tuberculosis diagnostic facilities





•  Smear microscopy
•  Xpert® MTB/RIF system for tuberculosis diagnosis
•  Electronic reporting systems
Potential antimicrobial resistance services:
•  Xpert® system for diagnosis of other infections 
(enterovirus; Clostridium difficile; hepatitis B virus; 
hepatitis C virus; human immunodeficiency virus; 
Chlamydia trachomatis and Neisseria gonorrhoeae; 
influenza and respiratory syncytial virus) 
•  Xpert® for drug resistance testing (carbapen-
em-resistant Enterobacteriaceae; methicillin-resis-
tant Staphylococcus aureus)
•  Point-of-care tests for detection of infections  
(FebriDx® Myxovirus resistance protein A and 
ImmunoPoC;™ urine dipstick; immunochromato-
graphic test for malaria; urinary antigen tests e.g. 
pneumococcus, Legionella)
Potential antimicrobial resistance services:
•  Blood automatic cultures (mini-BACTEC™); 
sputum cultures for bacterial pneumonia
•  Drug susceptibility testing (disk diffusion; VITEK® 
or Microscan® or agar dilution; Etest® minimum 
inhibitory concentration tests).
•  Line-probe assays (Helicobacter pylori)
•  Film-array tests (meningitis; respiratory and 
gastrointestinal infections; blood cultures).
Potential antimicrobial resistance services:
•  Organism identification by matrix-assisted laser 
desorption-ionization time-of-flight mass 
spectrometry and sequencing
•  Reference minimum inhibitory concentration 
testing
•  Population analysis profiling
Tuberculosis services:
•  Mycobacterium tuberculosis  identification and 
drug susceptibility testing
•  Liquid drug sensitivity testing (mycobacteria 
growth indicator tube)
•  Line-probe assays
Tuberculosis services:
•  Mycobacterium tuberculosis and nontuberculous 
mycobacteria identification and drug susceptibility 
testing
•  Minimum inhibitory concentration testing
•  Possibly genotyping or sequencing services
Notes: The following are trademark technologies: Xpert® (Cepheid, Sunnyvale, United States of America; USA); FebriDx® (RPS Diagnostics; Sarasota, USA); 
ImmunoPoC (MeMed Diagnostics, Israel); BACTEC (Becton Dickinson Diagnostics, Sparks, USA); VITEK® (bioMèrieux, Marcy-l’Étoile, France); Microscan® (Beckman 
Coulter, Brea, USA); Etest® (bioMérieux, Marcy l’Etoile, France).
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make them more suitable for interme-
diate or referral laboratories. Develop-
ments are underway, however, to make 
such tests more affordable and to bring 
them nearer to the point of care.
Newer, more expensive antibiotics 
are being developed to replace those 
made redundant due to high levels of 
drug resistance. From the perspective of 
an antimicrobial resistance programme 
these developments will also increase 
the need to improve access to effective 
diagnostic tools to rule out differential 
diagnoses.
Barriers to integration
A longstanding challenge is how to inte-
grate individual vertical disease control 
programmes with other vertical pro-
grammes and into primary health-care 
services.31,32 Concerns about the effects 
of integration on disease-specific fund-
ing and on human resources are com-
mon across many vertical programmes, 
such as those for tuberculosis, malaria 
and HIV.33 In the case of tuberculosis 
and antimicrobial resistance, challenges 
to integration may arise because pow-
erful stakeholders (such as the Global 
Fund to Fight AIDS, Tuberculosis and 
Malaria for tuberculosis and the Global 
Health Security Agenda focused on 
antibiotic resistance) largely operate 
independently of each other. Increasing 
integration between programmes would, 
by definition, require some relinquish-
ing of disease-specific resources to a 
common fund. The efficiencies achieved 
from joint service delivery would also 
likely result in job losses if human re-
source posts are merged, for example 
among laboratory staff who can perform 
diagnosis for both antimicrobial resis-
tance and tuberculosis, and this could 
be a source of conflict.
With different funding and account-
ability systems, the specific targets and 
institutional structures of programmes 
at the country level are also likely to be 
different. Coordination and commu-
nication across national tuberculosis 
control programmes, surveillance agen-
cies and laboratory services depart-
ments will be essential. This will require 
governance structures at the global and 
national levels so as to better integrate 
activities between programmes. Vertical 
programmes often work towards very 
focused targets.34 Therefore, ensur-
ing shared responsibility for mutually 
beneficial disease control targets, such 
as the number of symptomatic patients 
receiving point-of-care testing or the 
costs of diagnosis of patients, would 
be important. Developing integrated 
targets may work as one of the mecha-
nisms to incentivize collaboration and 
integration of services. A study from 
India illustrated how a vertical disease 
control programme with an explicit 
policy of strengthening local health 
systems helped to facilitate integration 
of vertical programmes.35
Technical guidelines for diagnos-
tic and antimicrobial stewardship will 
need to be redesigned, despite possible 
differences of opinion between disease-
specific technical experts.36,37 Currently, 
tuberculosis laboratories embedded 
within a well-structured vertical pro-
gramme have clear policies and guide-
lines for testing, interpreting results 
and treating patients. If tuberculosis 
laboratory services are to be expanded, 
guidelines on the use of diagnostics, in-
formation reporting protocols and man-
agement structures need to be updated. 
Such integration will require acceptance 
of new roles and new ways of working 
by the staff in laboratory systems. It 
will also create opportunities for ac-
cessing a larger patient population with 
a wider spectrum of infections, along 
with engaging health-care providers 
from various specialties and government 
bodies from different sectors. This can 
only be achieved through coordinated 
planning by antimicrobial resistance and 
tuberculosis control programmes at the 
country level; for example, to include 
managing the expanded remit of staff 
and their training in the use of a wider 
set of technologies.
Conclusions
Integration of the nascent antimicrobial 
resistance programmes within the well 
established vertical disease control pro-
grammes is currently limited. This re-
sults in missed opportunities for greater 
efficiency and better patient-centred 
care. The World Health Organization 
has highlighted gaps in coordination 
of information management systems in 
antimicrobial resistance programmes, 
such as for electronic reporting and tools 
for standardized surveillance.38 
Given the shift from conventional 
diagnostic tools to newer point-of-
care tests and the large investments in 
antimicrobial resistance surveillance,14 
we need to review the current role of 
diagnostic laboratories associated with 
disease-specific programmes. As newer 
multiplex point-of-care tests become 
increasingly available, the concept of 
programmes limited to diagnosis of a 
single disease will require rethinking. 
We argue that the tuberculosis laborato-
ry system, with its strong microbiology 
expertise and infrastructure, is particu-
larly well placed to contribute towards 
antimicrobial resistance control. Nev-
ertheless, integration of disease-specific 
programmes, which are not unique to 
tuberculosis, also faces longstanding 
barriers.
Many potential mutual benefits of 
integration exist, in terms of accelerated 
scale-up of diagnostic testing towards 
rational use of antimicrobial drugs as 
well as optimal use of resources. To 
scale-up activities, it would be prudent 
for governments to build on the exist-
ing regulatory frameworks, surveillance 
systems, infection control systems, 
laboratory infrastructure and human 
resources that are already in place to 
manage tuberculosis.19 Diagnostic tools, 
logistics and technologies for sharing 
data can be used to link programmes 
at the country level towards a stronger 
programme to control antimicrobial 
resistance including in tuberculosis. 
Not only would antimicrobial resistance 
programmes gain from the tuberculosis 
laboratory system, but tuberculosis 
programmes themselves would benefit 
from the political attention and fund-
ing currently being directed towards 
antimicrobial resistance.
In addition to the focus on budgets 
and resources, combined or integrated 
inter-programme activities bring other 
advantages. The main goal in partner-
ships in public health has been ensuring 
the future sustainability of programmes. 
By forging a partnership between anti-
microbial resistance and tuberculosis 
control programmes within countries’ 
governing structures, common goals 
will be safeguarded through a strength-
ened oversight mechanism. Moreover, 
programme integration presents op-
portunities to direct the focus of policy-
makers towards the issue of antimicro-
bial resistance, which has so far met 
with limited success.39 Advocacy efforts 
to influence pharmaceutical regulation, 
formulary restrictions and use of growth 
promoters in the veterinary industry 
could be intensified. Public health mes-
sages released by control programmes 
are useful catalysts for behavioural 
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change in communities. Reinforcement 
of such messages from tuberculosis 
clinics, as well as hospitals and clinics 
involved in antimicrobial resistance 
control efforts, is likely to lead to faster 
and more durable changes in antibiotic 
use, attitudes to infection prevention 
and general health awareness. ■
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صخلم
تابوركيلما تاداضم ةمواقمو لسلا ضرم ةحفاكم جمارب جمد
 هجاوت يتلاو – لخدلا ةطسوتمو ةضفخنم نادلبلا نم ديدعلا نياعت
 ضارملأاو  ،تابوركيلما  تاداضم  ةمواقم  نم  ةعفترم  تايوتسم
 ةعفترم  تلادعم  نم  –  لاعفلا  يرغ  جلاعلا  نع  ةتجانلا  ةبحاصلما
 ديدعلا  تماق ةيرخلأا دوقعلا  ىدم لىعو .لسلا  ضرمب ةباصلإل
 ةحفاكلم  ةلاعف  تامولعمو  تابرتمخ  ةمظنأ  ريوطتب  نادلبلا  نم
 تابرتخلما ةمظنأ عيسوت ةيفيك ريرقتلا اذه في فصنو .لسلا ضرم
 .تابوركيلما  تاداضم  ةمواقم  فئاظو  بعوتستل  ةدوجولما
 نع فشكلا في ديفي دق تامدلخا في عسوتلا اذه نأ فيك حضونو
 للاخ  نم  ةيبرتخلما  تاردقلا  فيو  لسلا  ضرمب  ةباصلإا  تلااح
 رزآتلا  هجوأ  صيخلتب  كلذك انمق  دقو .تابرتخلما  تامدخ جمد
 ينبو  لسلا  ضرم  عم  ةعبتلما  ىوتسلما  ةعيفر  تايجيتاترسلاا  ينب
 ةصنم  ميدقت  في  كلذ  مهاس  دقو  .تابوركيلما  تاداضم  ةحفاكم
 جمدلل  ليمعلا  قيبطتلا  ةيناكمإ  حيضوتو  جمابرلا  جمدل  ةلمتمح
 ةيصيخشتلا  تامدخلل  ةيحصلا  تامدلخا  ميدقت  ىوتسم  لىع
 عفانلما  نم  ديدعلا  دجوتو  .طسوتمو  ضفخنم  لخد  تاذ  ةئيب  في
 في عسوتلا  ةيرتو عيسرت ثيح نم كلذو جمدلل ةلمتحلما ةلدابتلما
 يرقاقعلل  ديشرلا  مادختسلاا  وحن  ةيصيخشتلا  تارابتخلاا  قاطن
 لدابتو دراوملل لثملأا مادختسلاا نع ًلاضف تابوركيملل ةداضلما
 تاونق عم ضرلما ةحفاكلم ةيسأرلا  جمابرلا  جمد نأ لاإ ،تابرلخا
 انمق دقو ،تايدحتلا نم وليخ يذلا رملأاب سيل ةلصفنلما ليومتلا





















Intégration des programmes de lutte contre la tuberculose et contre la résistance aux antimicrobiens
De nombreux pays à revenu faible et intermédiaire qui sont confrontés à 
une forte résistance aux antimicrobiens ainsi qu’à la morbidité associée, 
due à l’inefficacité des traitements, sont aussi fortement touchés 
par la tuberculose. Ces dernières décennies, de nombreux pays ont 
mis au point des systèmes efficaces d’information et de laboratoire 
afin de combattre la tuberculose. Dans cet article, nous décrivons 
la manière dont les systèmes existants des laboratoires spécialisés 
dans la tuberculose peuvent être élargis afin d’intégrer des fonctions 
applicables à la résistance aux antimicrobiens. Nous montrons comment 
cet élargissement des services pourrait contribuer au dépistage de la 
tuberculose et aux capacités des laboratoires par l’intégration de services 
de laboratoire. Nous faisons par ailleurs le point sur les synergies entre les 
stratégies de haut niveau sur la tuberculose et la lutte contre la résistance 
aux antimicrobiens. Celles-ci offrent des possibilités pour l’intégration 
de programmes et illustrent la manière dont l’intégration au niveau de 
la prestation des services de diagnostic pourrait se faire en pratique 
dans les régions à revenu faible et intermédiaire. L’intégration pourrait 
apporter de nombreux bénéfices mutuels, comme l’expansion plus 
rapide des tests de diagnostic en vue d’une utilisation rationnelle des 
médicaments antimicrobiens, d’une utilisation optimale des ressources 
et d’un partage d’expérience. L’intégration de programmes verticaux de 
lutte contre les maladies, qui ont des sources de financement différentes, 
n’est cependant pas chose simple. Nous évoquons également les 
obstacles à cette intégration ainsi que les perspectives et les mesures 
incitatives pour les surmonter.
Резюме
Интеграция программ по борьбе с туберкулезом и устойчивостью к противомикробным препаратам
Многие страны с низким и средним уровнем дохода, столкнувшиеся 
с высоким уровнем устойчивости к противомикробным 
препаратам и связанной с ней распространенностью случаев 
неэффективности лечения, помимо этого, имеют высокую 
заболеваемость туберкулезом. За последние десятилетия во 
многих странах были разработаны эффективные лабораторные 
и информационные системы борьбы с туберкулезом. В этой 
статье мы описываем, как существующие лабораторные системы 
для диагностики туберкулеза могут быть расширены путем 
включения методов определения лекарственной устойчивости 
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к противомикробным препаратам. Мы демонстрируем, как 
такое расширение сферы обслуживания может способствовать 
выявлению случаев туберкулеза и укреплению лабораторного 
потенциала за счет интеграции лабораторных услуг. Далее мы 
подводим итоги синергии между стратегиями высокого уровня 
по борьбе с туберкулезом и устойчивостью к противомикробным 
препаратам. Они обеспечивают потенциальную платформу 
для интеграции программ и иллюстрируют, каким образом на 
практике в условиях низкого и среднего уровня дохода можно 
было бы обеспечить интеграцию на уровне предоставления 
медицинских услуг для диагностических служб. Существует 
много аспектов потенциальной взаимной выгоды от интеграции 
с точки зрения ускоренного расширения диагностического 
тестирования в направлении рационального использования 
противомикробных препаратов, а также оптимального 
использования ресурсов и обмена опытом. Однако интеграция 
вертикальных программ борьбы с заболеваниями с раздельными 
потоками финансирования не лишена проблем, поэтому мы 
также обсуждаем препятствия на пути интеграции и выявляем 
возможности и стимулы для их преодоления.
Resumen
Integración de los programas de tuberculosis y control de resistencia a los antimicrobianos
Muchos países de ingresos bajos y medianos que enfrentan altos niveles 
de resistencia a los antimicrobianos, así como la morbilidad asociada 
por un tratamiento ineficaz, también presentan una alta incidencia de 
tuberculosis. En las últimas décadas, muchos países han desarrollado 
sistemas efectivos de laboratorio e información para el control de la 
tuberculosis. En este documento describimos cómo los sistemas de 
laboratorio de tuberculosis existentes pueden ampliarse para dar cabida 
a las funciones de resistencia a los antimicrobianos. Mostramos cómo 
dicha expansión en los servicios puede beneficiar la búsqueda de casos 
de tuberculosis y la capacidad de laboratorio a través de la integración de 
los servicios de laboratorio. Resumimos las sinergias entre las estrategias 
de alto nivel sobre la tuberculosis y el control de la resistencia a los 
antimicrobianos. Estos proporcionan una plataforma potencial para la 
integración de programas e ilustran cómo la integración en el nivel de 
prestación de servicios de salud para los servicios de diagnóstico podría 
ocurrir en la práctica en un entorno de ingresos bajos y medianos. Existen 
muchos beneficios mutuos potenciales de la integración, en términos de 
una mejora acelerada de las pruebas de diagnóstico hacia el uso racional 
de los medicamentos antimicrobianos, así como el uso óptimo de los 
recursos y el intercambio de experiencias. Sin embargo, la integración 
de programas de enfermedades verticales con flujos de financiación 
separados no está exenta de desafíos, y también examinamos los 
obstáculos a la integración e identificamos oportunidades e incentivos 
para superarlas.
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